Piramal Pharma · NSE: PPLPHARMA · BSE: 543635
Q4 FY23 results · Jan–Mar 2023
Piramal Pharma reported revenue from operations of ₹2,163.58 crore and net profit of ₹50.11 crore for Q4 FY23 (Jan–Mar 2023), on a consolidated basis.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,163.58 | — | — | 1,715.97 | +26.1% |
| Other income | 24.50 | — | — | 82.54 | −70.3% |
| Total income | 2,188.08 | — | — | 1,798.51 | +21.7% |
| Profit before share of associates & JVs and tax | 87.11 | — | — | (89.21) | Turned profit |
| Share of profit/(loss) of associates & JVs | 7.78 | — | 15.57 | ||
| Net profit for the period | 50.11 | — | — | (90.18) | Turned profit |
| EPS, basic (₹) | 0.42 | — | — | (0.76) | Turned profit |
| Net margin (%) | 2.3 | — | -5.3 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,054.58 | — | — | 813.29 | +29.7% |
| Other income | 62.88 | — | — | 53.88 | +16.7% |
| Total income | 1,117.46 | — | — | 867.17 | +28.9% |
| Profit before tax | 65.64 | — | — | 0.74 | 89x |
| Net profit for the period | 41.70 | — | — | (2.42) | Turned profit |
| EPS, basic (₹) | 0.35 | — | — | (0.02) | Turned profit |
| Net margin (%) | 4.0 | — | -0.3 |
Consolidated
- Filed with BSE
- 25 May 2023, 16:24 IST
- Board meeting
- 24 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 25 May 2023, 16:24 IST
- Board meeting
- 24 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE